|
|
Post by bthomas55ep on Oct 30, 2024 23:04:47 GMT -5
|
|
|
|
Post by porkini on Oct 31, 2024 7:05:55 GMT -5
Kinda weird, I just looked and sure enough, it is not posted under either Press Releases or Investor Press Releases. Also, first press release in a month, slow news month. IDK. I would hope that Investor Relations would be more on top of stuff like this and have the information posted up on their website first to lend credibility to their public postings when they get out there. michaelcastagna |
|
|
|
Post by derekewhitlock on Oct 31, 2024 7:32:11 GMT -5
Yep, strange indeed. Also, strange is that ever since we partnered with UTHR, MNKD would announce their earnings report one week after UTHR announced theirs and MNKD would hold their quarterly earnings call one week after UTHR's earnings call (give or take a day). Now, UTHR has completed their 3rd quarter earnings call and MNKD has yet to even announce date for their earnings report. I suspect this means nothing but it is a deviation from norm for the last 2 plus years.
|
|
|
|
Post by letitride on Oct 31, 2024 7:34:01 GMT -5
It was Dr Burkhard Blank CMO EVP R&D who made the statements and seems to have authored the PR. Looks like Mike is letting his Execs get more proactive. Lets Go!
|
|
|
|
Post by casualinvestor on Oct 31, 2024 9:07:04 GMT -5
Yep, strange indeed. Also, strange is that ever since we partnered with UTHR, MNKD would announce their earnings report one week after UTHR announced theirs and MNKD would hold their quarterly earnings call one week after UTHR's earnings call (give or take a day). Now, UTHR has completed their 3rd quarter earnings call and MNKD has yet to even announce date for their earnings report. I suspect this means nothing but it is a deviation from norm for the last 2 plus years. I've been waiting for the MNKD earnings announcement too. Binder moving on might be part of this delay |
|
|
|
Post by sr71 on Oct 31, 2024 9:52:11 GMT -5
OR ... The profits are so huge that it's taking a lot longer to tally it all up.  |
|
|
|
Post by dpjerryb on Oct 31, 2024 10:49:52 GMT -5
Am trying to check possible link of using clofazimine for treating chronic pseudomonas. Some where back when it may have been mentioned on MNKD mtg
|
|
|
|
Post by porkini on Oct 31, 2024 11:07:30 GMT -5
Kinda weird, I just looked and sure enough, it is not posted under either Press Releases or Investor Press Releases. Also, first press release in a month, slow news month. IDK. I would hope that Investor Relations would be more on top of stuff like this and have the information posted up on their website first to lend credibility to their public postings when they get out there. michaelcastagna I reached out to IR and received this response in less than an hour: "Thank you for reaching out to us. We issued the press release you mentioned in Australia alone, which is why it does not show up on the website or in the Globe Newswire feeds." |
|
|
|
Post by uvula on Oct 31, 2024 11:18:39 GMT -5
I looked at my Globe and Australia is on it.
|
|
|
|
Post by agedhippie on Oct 31, 2024 12:00:22 GMT -5
It showed up on the Bloomberg terminal  |
|
|
|
Post by Clement on Oct 31, 2024 12:03:08 GMT -5
It is now on Yahoo Finance.
|
|
|
|
Post by Clement on Oct 31, 2024 12:19:56 GMT -5
Yep, strange indeed. Also, strange is that ever since we partnered with UTHR, MNKD would announce their earnings report one week after UTHR announced theirs and MNKD would hold their quarterly earnings call one week after UTHR's earnings call (give or take a day). Now, UTHR has completed their 3rd quarter earnings call and MNKD has yet to even announce date for their earnings report. I suspect this means nothing but it is a deviation from norm for the last 2 plus years. I've been waiting for the MNKD earnings announcement too. Binder moving on might be part of this delay Maybe MNKD would like to announce late-breaking news prior to the EC and MNKD is waiting on final info. Maybe the news would relate to the "upcoming catalysts in Q4" which were mentioned in the Q2 EC. mnkd.proboards.com/post/268064/threadOne of those is nintedanib phase 1 readout ---- estimated study completion date is today. |
|
|
|
Post by prcgorman2 on Oct 31, 2024 19:23:10 GMT -5
Announcing trial in Australia is an administrative progress update. The updates that make a bigger difference are the ones that give indication of the results. I do like seeing that MannKind is executing on its business goals because it is good. It indicates professionalism and competence. The results I’m most anxious to see are the nintedanib DPI toxicity and Phase 1 readout. Being competent at business is good. Getting good results out of a pipeline candidate is even better.
|
|
|
|
Post by ktim on Oct 31, 2024 22:06:41 GMT -5
Could not have been said better. We will, hopefully, melt upward (at a fast pace) as milestones are met and prospects are derisked.
|
|
